Bristol-Myers Squibb Co (NYSE:BMY) has earned a consensus rating of “Hold” from the nineteen ratings firms that are currently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $66.05.
A number of research firms have weighed in on BMY. Jefferies Group set a $72.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday. BMO Capital Markets set a $51.00 target price on Bristol-Myers Squibb and gave the company a “sell” rating in a report on Wednesday, February 14th. Vetr raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 target price for the company in a report on Thursday, February 1st. Citigroup set a $78.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a report on Friday, February 16th. Finally, Credit Suisse Group set a $62.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, January 22nd.
Shares of Bristol-Myers Squibb (NYSE BMY) traded down $0.79 on Tuesday, reaching $67.84. The company had a trading volume of 4,122,989 shares, compared to its average volume of 8,563,402. Bristol-Myers Squibb has a 52 week low of $51.56 and a 52 week high of $70.05. The stock has a market cap of $111,520.00, a price-to-earnings ratio of 28.75, a P/E/G ratio of 2.11 and a beta of 1.08. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The company had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same quarter last year, the firm posted $0.63 EPS. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. sell-side analysts predict that Bristol-Myers Squibb will post 3.21 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.36%. The ex-dividend date of this dividend was Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 67.80%.
In other news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares in the company, valued at approximately $37,031,717.01. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Delphi Private Advisors LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $108,000. Massey Quick Simon & CO. LLC lifted its position in Bristol-Myers Squibb by 523.5% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 1,492 shares during the last quarter. Horan Capital Advisors LLC. bought a new stake in Bristol-Myers Squibb in the 3rd quarter worth approximately $122,000. NuWave Investment Management LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $119,000. Finally, Atlantic Trust LLC bought a new stake in Bristol-Myers Squibb in the 2nd quarter worth approximately $111,000. Institutional investors own 69.82% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.